Aradigm Corporation Logo

Print Print page   Email Email page   PDF Download PDF    Add to Briefcase
« Previous Release | Next Release »



Aradigm to Present at the Ladenburg Thalmann 2017 Healthcare Conference on September 26

HAYWARD, Calif.--(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq:ARDM) ("Aradigm" or the "Company") today announced that Aradigm management will present at the Ladenburg Thalmann 2017 Healthcare Conference on Tuesday, September 26, 2017, at 2:00 p.m. ET. The event will be held at the Sofitel New York in New York, New York.

Interested parties can access a live audio webcast and slide presentation at www.aradigm.com. An archived presentation will be available on the Company's Web site for 30 days.

About Aradigm

Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. Aradigm has completed two Phase 3 clinical trials with Linhaliq™, an investigational proprietary formulation of ciprofloxacin for inhalation, for the treatment of NCFBE and submitted a New Drug Application to the FDA for this indication. Aradigm's inhaled ciprofloxacin formulations, including Linhaliq, are also product candidates for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, and for the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever and inhaled anthrax.

More information about Aradigm can be found at www.aradigm.com.

Aradigm and the Aradigm Logo are registered trademarks of Aradigm Corporation.

Aradigm Corporation
Nancy Pecota, 510-265-8800
Chief Financial Officer

Source: Aradigm Corporation

News Provided by Acquire Media

Close window | Back to top